CN103293150A - Detection method of nafil medicines and detection kit - Google Patents
Detection method of nafil medicines and detection kit Download PDFInfo
- Publication number
- CN103293150A CN103293150A CN2013101866168A CN201310186616A CN103293150A CN 103293150 A CN103293150 A CN 103293150A CN 2013101866168 A CN2013101866168 A CN 2013101866168A CN 201310186616 A CN201310186616 A CN 201310186616A CN 103293150 A CN103293150 A CN 103293150A
- Authority
- CN
- China
- Prior art keywords
- solution
- acid
- sample
- medicines
- chloroform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a rapid detection method of nafil medicines, which successively comprises the following steps of: (1) taking a sample, and adding an acid solution to dissolve the sample; (2) adding an extraction agent to extract, and adding a buffer solution into extract; and (3) dropping a colour developing agent, and observing whether the solution is yellow or not, wherein if the solution is yellow, the sample contains nafil medicines, or else the sample does not contain nafil medicines. The invention further provides a special detection kit based on the method. The rapid detection method disclosed by the invention has the advantages of being low in analysis cost, free from special equipment, strong in specificity and high in sensitivity and is applied to testing whether nafil medicines are doped in medicines and health-care products in field; and the disadvantages in the prior art are overcome.
Description
Technical field
The present invention relates to a kind of detection method and detection kit of that non-class medicine.
Background technology
Phosphodiesterase is the negative growth factor of NO-cGMP path, it turns down The Effect of Nitric Oxide by the decomposition of catalysis cGMP, it is generally acknowledged that the nitrogen monoxide in the body is a factor of regulating the vascular smooth muscle expansion, thereby the result of phosphodiesterase effect is the contraction that promotes vascular smooth muscle.That non-class medicine can high selectivity the inhibition human body in 5 type phosphodiesterase (PDE5) activity, PDE5 is high in the penis sponge Level of Expression of Retinoic Acid, then expresses lower in its hetero-organization of human body and organ.After taking that non-class medicine, the diastole under the effect of medicine of corpora cavernosa penis vascular smooth muscle, blood flow increases, cavernous body hyperemia, telotism, thus generation is to the therapeutic action of penile erectile function obstacle.
That non-class medicine main adverse reactions comes from it to the inhibiting effect of other position phosphodiesterases of human body.Common bad reaction has: the paropsia of property is crossed in dizziness, nasal obstruction, indigestion and one, thisly may show as unusually that indigo plant/green color discrimination is unusual, light sensation strengthens or blurred vision.More than these bad reactions be because relevant smooth muscle relaxation causes mostly.That non-class medicine comparison serious adverse effects also comprises in addition: clinostatism blood pressure drops and cardiac output descend, clinical studies show is carried out sexual behaviour after taking that non-class medicine in addition, the probability that heart abnormality takes place increases, symptoms such as this comprises angina pectoris, dizziness, feel sick, and might cause sudden cardiac death.
In recent years, the situation of illegal that non-class medicine of interpolation is very serious in tonifying kidney and strengthening yang class Chinese medicine preparation and health products.The illegal activities of that non-class medicine are added in investigation without authorization in tonifying kidney and strengthening yang similar drug and health products, be a long-term task.Its coverage is wide, need carry out a large amount of checks, and carrying out this check activity in vast rural area and small and medium-sized cities underdeveloped has big difficulty.
In existing check medicine and the health products there be the method for that non-class medicine of doping:
1, thin-layered chromatography
Composition to be measured in the sample extracts with mixed solvent [ethanol-normal hexane-ammoniacal liquor (70:30:1)], and the need testing solution of gained and reference substance solution point launch with developping agent on same chromatographic sheet, after drying, examine under uviol lamp and show.Chromatogram spot (being lower than detection sensitivity) is not seen in Ruo Nafei class medicine reference substance spot relevant position, can think in the product and, should suspect to be mixed with that non-class medicine if obvious spot is arranged for being mixed with that non-class medicine.
The advantage of thin-layered chromatography is not need to use expensive analytical instrument.The shortcoming of this method is: (1) chromatographic resolution rate is lower, the health products complicated component, disturbing factor is many, easily some coexistence composition erroneous judgement is that non-class medicine, if some coexistence composition amount is big and chromatogram migration value with that non-class medicine approaching then can the jamming target composition detect.(2) development of chromatogram is long with the time of drying, and can not satisfy the requirement of quick mensuration.(3) require the experimenter that experience is preferably arranged.(4) fixing experiment place need be arranged, the mobile big scene of uncomfortable cooperation is detected.
2, high performance liquid chromatography
High performance liquid chromatography is the modern analysis method of using always.Under identical chromatographic condition, different materials has different chromatographic retentions.Identical be the need testing solution sample introduction respectively of that non-class solution control sample solution and sample extraction gained under the chromatographic condition, can detect that non-class content of medicines according to chromatographic retention.
The advantage of high performance liquid chromatography is chromatographic resolution efficient height, and is highly sensitive.Its shortcoming is: (1) instrument is expensive, and time for sample pretreatment is long, and great majority are at single product, and flowing of use mostly is a certain proportion of methyl alcohol and salt solusion mutually, needs after the test with big water gaging flushing chromatographic column, chromatographic column vulnerable to pollution, analysis cost height; (2) when the chromatographic retention of chromatographic retention and the silaenafil of coexistence composition near the time judgement that makes mistake of do easily; (3) instrument requires height to environment for use, needs fixedly put, and the mobile big scene of uncomfortable cooperation is detected.
3, high performance liquid chromatography-mass spectrometry method
Adopt the LC-MS technology, can further do mass spectrophotometry to isolated that the non-class medicine peak of high performance liquid chromatography and identify.Be applicable to complicated component, the sample analysis that background interference is serious, this analytical approach can improve the reliability of assay.
Shortcoming: analysis cost height, complicated operation; Instrument requires higher to environment for use, need fixedly to put, and the mobile big scene of uncomfortable cooperation is detected, and is difficult for promoting the use of.
Summary of the invention
The object of the present invention is to provide a kind of shortcoming that prior art exists that overcomes, analysis cost is low, do not need to use valuable analytical instrument, specificity is strong, highly sensitive, is applicable to whether field test medicine, health products mix the method for quick of that non-class medicine.
The method for quick of that non-class medicine of the present invention in turn includes the following steps:
(1) sample thief adds the acid solution extraction;
(2) add the extractant extraction, add damping fluid in the extract;
(3) add bromcresol green solution, observe solution and whether show yellow.
That non-class medicine has three nitrogen-atoms that can accept proton, in acid solution, accepts to generate with three positive charges behind three protons, be the kation of free state (with R
3+Expression).The existence of acid solution can strengthen that non-class medicine and generate free state kation (R
3+) ability, make free state kation (R in the solution
3+) higher concentration arranged.
Acid solution is a kind of in watery hydrochloric acid, dilute sulfuric acid or the phosphoric acid,diluted, and concentration is 0.01 ~ 0.1mol/L, or the mixed solution of aforementioned several acid solutions, is preferably 0.05mol/L watery hydrochloric acid.
Contain multiple auxiliary material or other compositions in medicine, the health products etc., after extraction, can minimize the composition in the medicine, reach and eliminate the purpose of disturbing.In the preferred phenixin of extractant, chloroform, the methylene chloride one or more, wherein chloroform is considered to the extractant of tool selectivity and accuracy through experiment.
Described damping fluid is selected from sodium citrate-hydrochloride buffer, glycocoll-hydrochloride buffer or sodium acetate-acetate buffer solution, and the pH of damping fluid is 1.5 ~ 2.5, preferred sodium acetate-acetate buffer solution.
In the step (3), if show yellow, then contain that non-class medicine in the sample, yellow then do not contain that non-class medicine in the sample if do not show.The speed of colour developing is relevant with that non-class drug concentrations in the solution.That non-class drug concentrations is more big, and the speed of colour developing is more fast.
In the said method, optimum experimental condition is to be based upon on the independent basis that changes of each parameter.
Further, if knownly contain any that non-class medicine, after the solution drying after the chromogenic reaction in the step (3), use determined by ultraviolet spectrophotometry concentration, namely survey its absorbance at the uv-absorption maximum wavelength place of this medicine, can obtain in the solution drug concentrations accurately according to its concentration-absorbance typical curve again.
Another object of the present invention is to provide the dedicated test kit of said method, described kit comprises: a kind of in (1) watery hydrochloric acid, dilute sulfuric acid or the phosphoric acid,diluted, concentration is 0.01 ~ 0.1mol/L, or the mixed solution of aforementioned several acid solutions, is preferably 0.05mol/L watery hydrochloric acid; (2) one or more in phenixin, chloroform, the methylene chloride, preferred chloroform; (3) sodium citrate-hydrochloride buffer, glycocoll-hydrochloride buffer or sodium acetate-acetate buffer solution, pH are 1.5 ~ 2.5, preferred sodium acetate-acetate buffer solution; (4) bromcresol green solution.
Compare with prior art, method of the present invention has following beneficial effect:
Analysis cost is low, do not need Special Equipment, specificity is strong, highly sensitive, be applicable to the method for quickly detecting that whether mixes that non-class medicine in field test medicine, the health products, overcome the shortcoming that prior art exists, satisfy the needs of medicine, health products supervision and inspection, provide screening test method fast for the specialized laboratories of checking medicine, health products whether to mix that non-class medicine simultaneously, to reach the reduction analysis cost, improve the purpose of checkability.Simultaneously, the present invention has also that anti-coexisting substances interference performance is strong, and experimental phenomena is obvious, check conclusion accuracy height, easy and simple to handle fast, do not need to use advantages such as expensive instrument.
The detection kit of that non-class medicine that the method according to this invention is made can satisfy the requirement that relevant food supervision and inspection is carried out in vast rural area.
Description of drawings
Fig. 1 is silaenafil concentration-ultraviolet absorptivity curve map.
Embodiment
Be described further below in conjunction with the present invention of embodiment, but be not construed as limiting the invention.
The detection of embodiment 1 power benefit gold autumn capsule (capsule, indicating dose is each 2, high effective liquid chromatography for measuring every of this product as a result contains that non-class medicine 58mg)
Get 0.5 amount content, grind evenly, place the 50mL beaker, add 25mL 0.05mol/L watery hydrochloric acid, mix, jolting two minutes was left standstill four minutes, filtered, and collected filtrate.Filtrate is transferred in the 125mL separating funnel, added the 5mL chloroform, jolting two minutes was left standstill one minute.Extract is transferred in the beaker of 50mL, and water continues to use 5mL chloroform extraction, combining extraction liquid.Sodium acetate-the acetate buffer solution that adds 3mL pH=2.0 in the extract, 2.5mL bromcresol green developer, solution shows yellow immediately, but contains that non-class medicine in the judgement sample thus.
Sample shreds into grain of rice size, and sampling 0.6g places the 50mL beaker, adds 25mL 0.01mol/L dilute sulfuric acid, mixes, and jolting two minutes (available glass rod is smash diffusing in case of necessity) was left standstill four minutes, filters and collects filtrate.Filtrate is transferred in the 125mL separating funnel, added the 5mL phenixin, jolting two minutes was left standstill one minute.Extract is transferred in the 50mL beaker, and water continues to use 5mL carbon tetrachloride extraction, combining extraction liquid.Sodium citrate-the hydrochloride buffer that adds 3mLpH=2.5 in the extract, 2.5mL bromcresol green developer, solution shows yellow immediately, but contains that non-class medicine in the judgement sample thus.
More than operation replaces filtration treatment with centrifugal treating, and effect is identical, but all contains that non-class medicine in the judgement sample.
0.5 of sample thief places the 50mL beaker, adds 25mL 0.1mol/L phosphoric acid,diluted, smashes diffusingly with glass rod, mixes, and jolting two minutes was left standstill four minutes, filtered and collected filtrate.Filtrate is transferred in the 125mL separating funnel, added the 5mL methylene chloride, jolting two minutes was left standstill one minute.Extract is transferred in the 50mL beaker, and water continues to use 5mL dichloromethane extraction, combining extraction liquid.Glycocoll-the hydrochloride buffer that adds 3mLpH=1.5 in the extract, 2.5mL bromcresol green developer, solution shows yellow immediately, but contains that non-class medicine in the judgement sample thus.
The very simple tonic tablet for kidney-reinforcing of embodiment 4 detects (indicating dose is each 5 for tablet, bronzing dressing, and efficient liquid-phase chromatography method detects and confirms not contain that non-class medicine)
1 of sample thief, crushing is placed in the 50mL beaker, adds 25mL mixed acid solution (0.05mol/L watery hydrochloric acid: 0.01mol/L dilute sulfuric acid: 0.1mol/L phosphoric acid,diluted volume ratio is 2:2:1), mixes, and jolting two minutes was left standstill four minutes, filtered and collected filtrate.Filtrate is transferred in the 125mL separating funnel, added the 5mL chloroform, jolting two minutes was left standstill one minute.Extract is transferred in the 50mL beaker, and water continues to use 5mL chloroform extraction, combining extraction liquid.Sodium acetate-the acetate buffer solution that adds 3mLpH=2.0 in the extract, 2.5mL bromcresol green developer, solution does not show yellow, leaving standstill after three minutes does not still have yellow to show, but does not contain that non-class medicine in the judgement sample thus.
Whether there is the experiment of that non-class medicine in embodiment 5 medicines, the health products
Adopt the method for embodiment 1 to detect 10 batches of commercially available samples (being denoted as medicine, health products).And adopt LCMS method and testing result comparison, the result is as follows:
| Goods # | Explanation | Sampling amount | The colour developing result | Identification result |
The mass |
| Sample | |||||
| 1 | |
1, grind | Colour developing is yellow immediately | Positive | Contain |
| Sample | |||||
| 2 | |
1, grind | Displaing yellow not in 30 seconds | Negative | Do not contain that |
| Sample | |||||
| 3 | |
1 intragranular is tolerant | Colour developing is yellow immediately | Positive | Contain Vardenafil |
| Sample 4 | |
1 intragranular is tolerant | 30 seconds not interior displaing yellows | Negative | Do not contain that non-class medicine |
| Sample 5 | |
1 intragranular is tolerant | 30 seconds not interior displaing yellows | Negative | Do not contain that non-class medicine |
| Sample-6 | |
1/2 | Displaing yellow not in 30 seconds | Negative | Do not contain that non-class medicine |
| Sample 7 | Medicinal tea | 0.5g | Displaing yellow in 20 seconds | Positive | Contain silaenafil |
| Sample 8 | Medicinal tea | 0.5g | Displaing yellow not in 30 seconds | Negative | Do not contain that non-class medicine |
| Sample 9 | |
1 intragranular is tolerant | Displaing yellow not in 30 seconds | Negative | Do not contain that non-class medicine |
| Sample 10 | Cassia seed | 0.5g | Displaing yellow not in 30 seconds | Negative | Do not contain that non-class medicine |
The checking of above-mentioned experimental result and second order ms is the result show, the positive report of none official holiday of detection method of the present invention, and the also any sample that contains that non-class medicine of omission not simultaneously, the result is accurately and reliably.
Measure 7 samples that above-mentioned that non-class drug test is negative and reacts by the described sampling of the inventive method, and mix silaenafil reference substance 20mg respectively, test by the inventive method, the result all is positive, show that this method has good antijamming capability, specificity is strong, and good accuracy is arranged.
The detection limit of embodiment 6 synthetic samples detects
Sample: the silaenafil of massfraction more than 99.5%
Add 2mg, 5mg, 10mg, 20mg silaenafil respectively in 10mL sample bottle I, II, III, IV, add 25mL0.05mol/L watery hydrochloric acid respectively, mix, jolting two minutes was left standstill four minutes, filtered and collected filtrate.Filtrate is transferred in the 125mL separating funnel, added the 5mL chloroform, jolting two minutes was left standstill one minute.Extract is transferred in the 50mL beaker, and water continues to use 5mL chloroform extraction, combining extraction liquid.The damping fluid that adds 3mLpH=2.0 in the extract, 2.5mL bromcresol green developer is surveyed its absorbance at the 415nm place, according to typical curve, records its accurate content and is respectively 0.05mg, 0.489mg, 9.96mg, 18.85mg.
Experimental result:
Solution colour does not change in the color comparison tube I, and solution shows yellow in color comparison tube II, III, the IV, this shows that detecting of this method is limited to 5mg.
The sensitivity of embodiment 7 synthetic samples detects
Sample: the silaenafil of massfraction more than 99.5%
Adopt the detection method of embodiment 1, prepare the silaenafil solution of a series of variable concentrations, can get curve as shown in Figure 1 according to absorbance.When content less than 0.5gL
-1The time, the solution absorbency value is almost constant, and color does not change substantially, and naked eyes can't be judged; When content greater than 0.5gL
-1The time, concentration becomes good linear relationship with absorbance, and change color is obvious, therefore can determine tentatively that the sensitivity of this method is 0.5gL
-1
Above embodiment is only in order to illustrate technical scheme of the present invention but not limiting the scope of the invention; although with reference to preferred embodiment the present invention has been done detailed description; those of ordinary skill in the art is to be understood that; can make amendment or be equal to replacement technical scheme of the present invention, and not break away from essence and the scope of technical solution of the present invention.
Claims (7)
1. the detection method of that non-class medicine in turn includes the following steps:
(1) sample thief adds acid leach solution;
(2) add the extractant extraction, add damping fluid in the extract;
(3) dripping bromine cresols green solution is observed solution and whether is shown yellow;
Wherein: described acid solution is a kind of in watery hydrochloric acid, dilute sulfuric acid or the phosphoric acid,diluted, and concentration is 0.01 ~ 0.1mol/L, or the mixed solution of aforementioned several acid solutions;
Described extractant is one or more in phenixin, chloroform, the methylene chloride;
Described damping fluid is sodium citrate-hydrochloride buffer, glycocoll-hydrochloride buffer or sodium acetate-acetate buffer solution, and the pH of described damping fluid is 1.5 ~ 2.5.
2. the method for claim 1, it is characterized in that: described acid solution is 0.05mol/L watery hydrochloric acid.
3. the method for claim 1, it is characterized in that: described extractant is chloroform.
4. the method for claim 1, it is characterized in that: described damping fluid is sodium acetate-acetate buffer solution.
5. as the method for claim 1-4 described in each, it is characterized in that: described method also comprises: after the solution drying after the chromogenic reaction in the described step (3), adopt the determined by ultraviolet spectrophotometry drug concentrations.
6. dedicated test kit as the method for claim 1-5 described in each, it is characterized in that: described kit comprises: (1) concentration is watery hydrochloric acid, dilute sulfuric acid or the phosphoric acid,diluted of 0.01 ~ 0.1mol/L, or the mixed acid solution of aforementioned several acid solutions; (2) one or more in phenixin, chloroform, the methylene chloride; (3) sodium citrate-hydrochloride buffer, glycocoll-hydrochloride buffer or sodium acetate-acetate buffer solution, pH1.5 ~ 2.5; (4) bromcresol green solution.
7. kit as claimed in claim 6, it is characterized in that: described kit comprises: (1) 0.05mol/L watery hydrochloric acid; (2) chloroform (3) pH1.5 ~ 2.5 sodium acetates-acetate buffer solution; (4) bromcresol green solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186616.8A CN103293150B (en) | 2013-05-17 | 2013-05-17 | Detection method of nafil medicines and detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186616.8A CN103293150B (en) | 2013-05-17 | 2013-05-17 | Detection method of nafil medicines and detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103293150A true CN103293150A (en) | 2013-09-11 |
| CN103293150B CN103293150B (en) | 2015-03-11 |
Family
ID=49094389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310186616.8A Active CN103293150B (en) | 2013-05-17 | 2013-05-17 | Detection method of nafil medicines and detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103293150B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1405314A (en) * | 2001-08-17 | 2003-03-26 | 杭州泰士生物科技有限公司 | Cryptoporus volvatus fermented product, and its preparation method and application |
| CN1563953A (en) * | 2004-03-24 | 2005-01-12 | 广东省药品检验所 | Fast analyzing method for sildenafil citrate doped medicine, health products and foods |
| US20050171449A1 (en) * | 2000-03-21 | 2005-08-04 | Suslick Kenneth S. | Method and apparatus for detecting ammonia from exhaled breath |
| CN101021479A (en) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | Method for assaying cedinafei and derivative thereof |
| WO2012042185A2 (en) * | 2010-09-30 | 2012-04-05 | Ceca S.A. | Solvents for the determination of amines in water |
-
2013
- 2013-05-17 CN CN201310186616.8A patent/CN103293150B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171449A1 (en) * | 2000-03-21 | 2005-08-04 | Suslick Kenneth S. | Method and apparatus for detecting ammonia from exhaled breath |
| CN1405314A (en) * | 2001-08-17 | 2003-03-26 | 杭州泰士生物科技有限公司 | Cryptoporus volvatus fermented product, and its preparation method and application |
| CN1563953A (en) * | 2004-03-24 | 2005-01-12 | 广东省药品检验所 | Fast analyzing method for sildenafil citrate doped medicine, health products and foods |
| CN101021479A (en) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | Method for assaying cedinafei and derivative thereof |
| WO2012042185A2 (en) * | 2010-09-30 | 2012-04-05 | Ceca S.A. | Solvents for the determination of amines in water |
Non-Patent Citations (2)
| Title |
|---|
| 吴英,谢红伟: "溴甲酚绿分光光度法测定麻黄碱含量的研究", 《分析科学学报》, vol. 23, no. 2, 30 April 2007 (2007-04-30) * |
| 江虹,等: "亚甲基蓝光度法测定西地那非的含量", 《分析科学学报 》, vol. 20, no. 3, 30 June 2004 (2004-06-30), pages 287 - 289 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103293150B (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Development of an immunoaffinity chromatography and HPLC-UV method for determination of 16 sulfonamides in feed | |
| CN101581712B (en) | Quick test method of biguanide compounds added in hypoglycemic medicine, health care products or food and application thereof | |
| CN104535702A (en) | Method used for detecting multiple trace drug pollutants in drinking water simultaneously | |
| CN102393391B (en) | Rapid measurement method of melatonin doped in Chinese patent medicine and healthcare food | |
| CN102519956B (en) | Quick phenolphthalein testing method and test paper utilizing same | |
| Acharya et al. | Pharmacognostic standardization of Grifola frondosa: A well-studied medicinal mushroom | |
| Badr et al. | Validated HPLC method for simultaneous estimation of khellol glucoside, khellin and visnagin in Ammi visnaga L. fruits and pharmaceutical preparations | |
| CN103926340A (en) | Method for measuring nitrofuran antibiotics in cosmetics | |
| CN105510312B (en) | A kind of method for quick of orlistat | |
| CN104215480A (en) | Method for rapid detection of promazine substances in product | |
| CN102818863B (en) | Method for identifying proanthocyanidins in ginkgo leaf preparation | |
| CN103852555B (en) | A kind of quality determining method of Tibetan medicinal composition rheumatism Sialon preparation | |
| CN107703080A (en) | A kind of assay method of dandelion extract general flavone content | |
| CN103278498A (en) | Detecting method and kit of sibutramine hydrochloride | |
| CN101365952B (en) | Assay, kit and apparatus for detection of artemisinin derivatives | |
| CN103293150B (en) | Detection method of nafil medicines and detection kit | |
| CN103316102A (en) | Detection method for external traditional Chinese medicine preparation for treating haemorrhoids | |
| CN110057936A (en) | A kind of content assaying method of vitamin E | |
| CN101692079A (en) | Rapid detection method and rapid detection kit of fluoroquinolone antibiotics | |
| CN110967430B (en) | Method for measuring dissolution curve of coenzyme Q10 capsule | |
| Campíns-Falcó et al. | Improved detection limits for screening of diuretics by coupled liquid chromatography and ultraviolet—visible spectrophotometry | |
| CN103267759B (en) | A kind of detection method of thiazolidine ketone medicine and detection kit | |
| Dasgupta et al. | Rapid detection of oleander poisoning by Digoxin III, a new Digoxin assay: impact on serum Digoxin measurement | |
| CN104215670B (en) | The quickly method of phenytoin Sodium analog in detection goods | |
| CN102445447B (en) | Method for rapid detection of levonorgestral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |